Richard M. Lee‐Ying

PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium

Dominick Bossé, Jamison Mercer, Soundouss Raissouni et al. · Clinical Colorectal Cancer · 2016 · 71 citations

Medicine, Oncology, Surgery +16

The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study

Jeenan Kaiser, Haocheng Li, Scott North et al. · Bladder Cancer · 2018 · 26 citations · Full text

Medicine, Oncology, Urology +15

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab

Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers et al. · Cancer Medicine · 2020 · 24 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world

Mita Manna, Richard M. Lee‐Ying, Gwynivere A Davies et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 22 citations

Medicine, Hematology, Oncology +13

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Edoardo Francini, Francesca Montagnani, Pier Vitale Nuzzo et al. · JAMA Network Open · 2021 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17